Zhitong Finance App News, Xiansheng Pharmaceutical (02096) announced that on November 2, 2026, the Group and Lingke Pharmaceutical (Zhejiang) Co., Ltd. (Lingke Pharmaceutical) reached further cooperation on the selective JAK1 inhibitor zeprixitinib. The Group will receive exclusive commercial rights in mainland China, Hong Kong, Macao and Taiwan for moderate to severe atopic dermatitis (AD) and other dermatological indications in adults.
The Group and Linke Pharmaceuticals reached a cooperation in March 2022 to obtain exclusive commercialization rights for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in mainland China, Hong Kong, Macao and Taiwan. This cooperation will further expand the commercialization potential of zeprixitinib and improve the Group's product layout in the field of autoimmune diseases.
Zepcitinib is a highly selective, oral second-generation JAK1 inhibitor independently developed by Linke Pharmaceuticals. It is currently being developed to treat inflammatory and autoimmune diseases including rheumatoid arthritis, atopic dermatitis, and ankylosing spondylitis. Zeprixitinib has completed a critical phase III clinical study for atopic dermatitis, and a new drug marketing application (NDA) for the treatment of moderate to severe AD was accepted by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) in April 2026. A phase III clinical study of zepcitinib for rheumatoid arthritis has been completed, and a phase III clinical development project for ankylosing spondylitis is also ongoing.